A likely explanation for the reported elevation of CXCL9 in patients with MASLD might be positive feedback and upregulation of this protein to counteract the fibrotic milieu within damaged liver cells. This evidence concerns the gene CXCL9 and metabolic dysfunction-associated steatotic liver disease.